The cancer center selected Evident’s Pramana technology to support clinical and research programs, with full digital adoption planned by 2027.
Moffitt Cancer Center has selected Evident’s Pramana high-throughput scanning system as part of a strategic partnership to expand digital pathology capabilities across its clinical and research operations.
The agreement includes the initial acquisition of four scanners, with installation expected to begin later this year. The phased implementation represents part of Moffitt’s broader digital transformation strategy, with full digital adoption anticipated by 2027.
“Digital pathology is critical to advancing precision oncology,” says Karen Lu, MD, executive vice president and physician-in-chief at Moffitt Cancer Center, in a release. “Integrating Evident’s Pramana systems into our laboratories will enhance efficiency, strengthen diagnostic accuracy, and accelerate our progress toward a fully digital environment, ultimately supporting better outcomes for the patients we serve.”
System Supports Multiple Slide Types
After conducting an evaluation, Moffitt selected the Pramana system based on its ability to deliver high-quality images while accommodating various slide types, including cytology and blood smears, within a single platform. The system is designed to simplify workflows and reduce training requirements through an intuitive interface.
“Moffitt is committed to adopting technologies that support both clinical care and research innovation,” says William Westra, MD, vice chair of pathology at Moffitt Cancer Center, in a release. “Evident’s Pramana technology will allow us to process a broader range of slide types, reduce reliance on additional staffing, and lay the groundwork for future integration of AI tools.”
The Pramana scanners feature a built-in workflow designed to minimize disruption as laboratories transition to digital operations. This approach provides what Evident describes as a practical path for institutions adopting digital pathology at scale.
“Evident is proud to work with Moffitt Cancer Center as it advances its digital pathology program,” says Wes Pringle, Evident CEO, in a release. “By integrating Pramana systems, Moffitt gains the image quality and operational efficiency needed today, along with a forward-thinking platform designed to support emerging technologies like AI.”
Evident, formerly known as Olympus, recently acquired Pramana Inc. The company has operated in optical precision and microscopy for over 100 years, offering imaging solutions that span research, clinical diagnostics, and education applications.
The implementation will include validation phases as Moffitt expands its digital pathology capabilities over the coming months.
ID 67557460 © Chengusf | Dreamstime.com
